Report Detail
Global Acilizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4706220 |
- 09 June, 2026 |
- Global |
- 89 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Acilizumab market size was valued at US$ 350 million in 2025 and is forecast to a readjusted size of US$ 1055 million by 2032 with a CAGR of 10.9% during review period.
Acilizumab is a monoclonal antibody drug that targets the interleukin-6 (IL-6) pathway. It exerts anti-inflammatory and immunomodulatory effects by binding to the IL-6 receptor and inhibiting inflammatory signal transduction. The drug is widely used in the treatment of autoimmune diseases such as rheumatoid arthritis, and it also has significant clinical value in inflammatory conditions like cytokine release syndrome. As a biologic agent, Acilizumab demonstrates high specificity and efficacy, showing notable benefits in improving patient symptoms and slowing disease progression, and has become an important therapeutic option in the field of IL-6 inhibitors.In 2025, global production of axatilimab reached approximately 15,000 vials.
Acilizumab, as a monoclonal antibody targeting the interleukin-6 (IL-6) pathway, holds an important position in the treatment market for autoimmune and inflammatory diseases. With the continuous increase in the number of patients with chronic conditions such as rheumatoid arthritis, along with the growing demand for precise immunomodulatory therapies, the IL-6 inhibitor market is maintaining steady growth. From a competitive landscape perspective, the field consists of originator drugs and multiple biosimilars, leading to intensifying competition, which in turn improves product accessibility and drives price reductions. On a global scale, Acilizumab has strong penetration in hospital channels and specialty care settings, with particularly significant growth potential in emerging markets. Looking ahead, with further expansion of indications (such as inflammatory syndromes) and broader medical insurance coverage, the market size of Acilizumab is expected to continue growing, maintaining its important role in the IL-6 targeted therapy landscape.
This report is a detailed and comprehensive analysis for global Acilizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Acilizumab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Acilizumab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Acilizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Acilizumab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Acilizumab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Acilizumab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Chugai Pharmaceutical, F. Hoffmann-La Roche, Genentech, Celltrion, Fresenius Kabi, Biogen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Acilizumab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Intravenous, IV
Subcutaneous, SC
Market segment by Specifications
80 mg / 4 mL
200 mg / 10 mL
Market segment by Production Technology
Innovator
Generic
Market segment by Sales Channels
Hospital
Retail
Online
Market segment by Application
Rheumatoid Arthritis, RA
Systemic Juvenile Idiopathic Arthritis
Cytokine Release Syndrome (CRS)
Giant Cell Arteritis, GCA
Others
Major players covered
Chugai Pharmaceutical
F. Hoffmann-La Roche
Genentech
Celltrion
Fresenius Kabi
Biogen
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Acilizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Acilizumab, with price, sales quantity, revenue, and global market share of Acilizumab from 2021 to 2026.
Chapter 3, the Acilizumab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acilizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Acilizumab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Acilizumab.
Chapter 14 and 15, to describe Acilizumab sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Acilizumab Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Intravenous, IV
- 1.3.3 Subcutaneous, SC
- 1.4 Market Analysis by Specifications
- 1.4.1 Overview: Global Acilizumab Consumption Value by Specifications: 2021 Versus 2025 Versus 2032
- 1.4.2 80 mg / 4 mL
- 1.4.3 200 mg / 10 mL
- 1.5 Market Analysis by Production Technology
- 1.5.1 Overview: Global Acilizumab Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
- 1.5.2 Innovator
- 1.5.3 Generic
- 1.6 Market Analysis by Sales Channels
- 1.6.1 Overview: Global Acilizumab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospital
- 1.6.3 Retail
- 1.6.4 Online
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Acilizumab Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Rheumatoid Arthritis, RA
- 1.7.3 Systemic Juvenile Idiopathic Arthritis
- 1.7.4 Cytokine Release Syndrome (CRS)
- 1.7.5 Giant Cell Arteritis, GCA
- 1.7.6 Others
- 1.8 Global Acilizumab Market Size & Forecast
- 1.8.1 Global Acilizumab Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Acilizumab Sales Quantity (2021-2032)
- 1.8.3 Global Acilizumab Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Chugai Pharmaceutical
- 2.1.1 Chugai Pharmaceutical Details
- 2.1.2 Chugai Pharmaceutical Major Business
- 2.1.3 Chugai Pharmaceutical Acilizumab Product and Services
- 2.1.4 Chugai Pharmaceutical Acilizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Chugai Pharmaceutical Recent Developments/Updates
- 2.2 F. Hoffmann-La Roche
- 2.2.1 F. Hoffmann-La Roche Details
- 2.2.2 F. Hoffmann-La Roche Major Business
- 2.2.3 F. Hoffmann-La Roche Acilizumab Product and Services
- 2.2.4 F. Hoffmann-La Roche Acilizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 F. Hoffmann-La Roche Recent Developments/Updates
- 2.3 Genentech
- 2.3.1 Genentech Details
- 2.3.2 Genentech Major Business
- 2.3.3 Genentech Acilizumab Product and Services
- 2.3.4 Genentech Acilizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Genentech Recent Developments/Updates
- 2.4 Celltrion
- 2.4.1 Celltrion Details
- 2.4.2 Celltrion Major Business
- 2.4.3 Celltrion Acilizumab Product and Services
- 2.4.4 Celltrion Acilizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Celltrion Recent Developments/Updates
- 2.5 Fresenius Kabi
- 2.5.1 Fresenius Kabi Details
- 2.5.2 Fresenius Kabi Major Business
- 2.5.3 Fresenius Kabi Acilizumab Product and Services
- 2.5.4 Fresenius Kabi Acilizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Fresenius Kabi Recent Developments/Updates
- 2.6 Biogen
- 2.6.1 Biogen Details
- 2.6.2 Biogen Major Business
- 2.6.3 Biogen Acilizumab Product and Services
- 2.6.4 Biogen Acilizumab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Biogen Recent Developments/Updates
3 Competitive Environment: Acilizumab by Manufacturer
- 3.1 Global Acilizumab Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Acilizumab Revenue by Manufacturer (2021-2026)
- 3.3 Global Acilizumab Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Acilizumab by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Acilizumab Manufacturer Market Share in 2025
- 3.4.3 Top 6 Acilizumab Manufacturer Market Share in 2025
- 3.5 Acilizumab Market: Overall Company Footprint Analysis
- 3.5.1 Acilizumab Market: Region Footprint
- 3.5.2 Acilizumab Market: Company Product Type Footprint
- 3.5.3 Acilizumab Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Acilizumab Market Size by Region
- 4.1.1 Global Acilizumab Sales Quantity by Region (2021-2032)
- 4.1.2 Global Acilizumab Consumption Value by Region (2021-2032)
- 4.1.3 Global Acilizumab Average Price by Region (2021-2032)
- 4.2 North America Acilizumab Consumption Value (2021-2032)
- 4.3 Europe Acilizumab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Acilizumab Consumption Value (2021-2032)
- 4.5 South America Acilizumab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Acilizumab Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Acilizumab Sales Quantity by Type (2021-2032)
- 5.2 Global Acilizumab Consumption Value by Type (2021-2032)
- 5.3 Global Acilizumab Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Acilizumab Sales Quantity by Application (2021-2032)
- 6.2 Global Acilizumab Consumption Value by Application (2021-2032)
- 6.3 Global Acilizumab Average Price by Application (2021-2032)
7 North America
- 7.1 North America Acilizumab Sales Quantity by Type (2021-2032)
- 7.2 North America Acilizumab Sales Quantity by Application (2021-2032)
- 7.3 North America Acilizumab Market Size by Country
- 7.3.1 North America Acilizumab Sales Quantity by Country (2021-2032)
- 7.3.2 North America Acilizumab Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Acilizumab Sales Quantity by Type (2021-2032)
- 8.2 Europe Acilizumab Sales Quantity by Application (2021-2032)
- 8.3 Europe Acilizumab Market Size by Country
- 8.3.1 Europe Acilizumab Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Acilizumab Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Acilizumab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Acilizumab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Acilizumab Market Size by Region
- 9.3.1 Asia-Pacific Acilizumab Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Acilizumab Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Acilizumab Sales Quantity by Type (2021-2032)
- 10.2 South America Acilizumab Sales Quantity by Application (2021-2032)
- 10.3 South America Acilizumab Market Size by Country
- 10.3.1 South America Acilizumab Sales Quantity by Country (2021-2032)
- 10.3.2 South America Acilizumab Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Acilizumab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Acilizumab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Acilizumab Market Size by Country
- 11.3.1 Middle East & Africa Acilizumab Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Acilizumab Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Acilizumab Market Drivers
- 12.2 Acilizumab Market Restraints
- 12.3 Acilizumab Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Acilizumab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Acilizumab
- 13.3 Acilizumab Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Acilizumab Typical Distributors
- 14.3 Acilizumab Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Acilizumab. Industry analysis & Market Report on Acilizumab is a syndicated market report, published as Global Acilizumab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Acilizumab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
